Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia

Omer Kucuk*, Larry Kilton, James L. Wade, Richard Blough, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations


Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number4
StatePublished - Dec 1 2000



  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Menogaril
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this